Indeed, in cell lines and tumors from patients with gliomas, lung cancer, colorectal cancer, prostate cancer, and head and neck cancer, hypermethylation of the Keap1 promoter has been observed (Hanada et al., 2012, Martinez et al., 2014, Muscarella et al., 2011, Wang et al., 2008, Zhang et al., 2010). Here, KEAP1 is linked to lung carcinoma.